XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
STOCK-BASED COMPENSATION (Tables)
9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
A summary of the stock option activity for the nine months ended September 30, 2023 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Exercise
Price
Options outstanding at December 31, 20220.7 $13.38 
Less:
Options exercised— $— 
Options canceled or expired— $— 
Options outstanding at September 30, 20230.7 $13.38 
Options exercisable at September 30, 20230.5 $13.38 
Schedule of Restricted Stock Unit Activity
A summary of the RSU awards activity under the Company’s equity plan and inducement awards, including PSU awards, for the nine months ended September 30, 2023 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Grant Date
Fair Value
RSUs unvested and outstanding at December 31, 20223.7 $25.08 
RSUs granted2.1 $23.57 
Less:
RSUs vested(1.0)$24.95 
RSUs canceled(0.2)$24.95 
RSUs unvested and outstanding at September 30, 20234.6 $24.41 
Schedule of Shares Purchased and Compensation Expense Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the three and nine months ended September 30, 2023 and 2022 are as follows:
Three months ended
September 30,
Nine months ended
September 30,
(in millions)2023202220232022
Shares purchased under the plan
— — 0.2 0.2
Plan compensation expense$0.5 $0.5 $1.7 $1.4 
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:
Three months ended
September 30,
Nine months ended
September 30,
(in millions)2023202220232022
Cost of testing revenue$0.4 $0.5 $1.1 $1.3 
Research and development expense1.2 1.0 2.9 4.4 
Selling, general, and administrative expense10.0 7.9 26.3 24.2 
     Total stock-based compensation expense$11.6 $9.4 $30.3 $29.9